Physician profile
Trystan J Crook
NPI 1437146214
$14,911.80
in general payments reported to CMS, 2019-2025
67 companies · $2,082 in 2025
The $2,082 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,277 · 2020: $530 · 2021: $2,494 · 2022: $2,740 · 2023: $2,538 · 2024: $2,250 · 2025: $2,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,870.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,470.74 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $1,464.54 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,306.92 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $965.28 | 2019-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $858.87 | 2019-2025 | Jardiance |
| Pfizer INC. | $698.37 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $652.34 | 2019-2025 | Xifaxan, Plenvu |
| Astrazeneca Pharmaceuticals LP | $618.01 | 2019-2025 | Airsupra, Farxiga, Fasenra |
| Merck Sharp & Dohme LLC | $434.95 | 2019-2024 | Gardasil 9, Belsomra, Capvaxive |
| Antares Pharma, INC. | $415.73 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Otsuka America Pharmaceutical, INC. | $380.08 | 2021-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $303.41 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $271.84 | 2019-2022 | |
| Glaxosmithkline, LLC. | $241.58 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $236.32 | 2019-2025 | Vpriv, Trintellix |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trystan Crook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.